nodes	percent_of_prediction	percent_of_DWPC	metapath
Emtricitabine—Hyperbilirubinaemia—Docetaxel—skin cancer	0.00365	0.00365	CcSEcCtD
Emtricitabine—Malnutrition—Imiquimod—skin cancer	0.00364	0.00364	CcSEcCtD
Emtricitabine—Myalgia—Vemurafenib—skin cancer	0.00364	0.00364	CcSEcCtD
Emtricitabine—Arthralgia—Vemurafenib—skin cancer	0.00364	0.00364	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00361	0.00361	CcSEcCtD
Emtricitabine—Vomiting—Vismodegib—skin cancer	0.00359	0.00359	CcSEcCtD
Emtricitabine—Rash—Vismodegib—skin cancer	0.00356	0.00356	CcSEcCtD
Emtricitabine—Dermatitis—Vismodegib—skin cancer	0.00356	0.00356	CcSEcCtD
Emtricitabine—Back pain—Imiquimod—skin cancer	0.00352	0.00352	CcSEcCtD
Emtricitabine—Dermatitis bullous—Fluorouracil—skin cancer	0.0035	0.0035	CcSEcCtD
Emtricitabine—Bone pain—Docetaxel—skin cancer	0.00347	0.00347	CcSEcCtD
Emtricitabine—Infection—Vemurafenib—skin cancer	0.00346	0.00346	CcSEcCtD
Emtricitabine—Inflammation—Docetaxel—skin cancer	0.00342	0.00342	CcSEcCtD
Emtricitabine—Nervous system disorder—Vemurafenib—skin cancer	0.00342	0.00342	CcSEcCtD
Emtricitabine—Skin disorder—Vemurafenib—skin cancer	0.00339	0.00339	CcSEcCtD
Emtricitabine—Weight decreased—Bleomycin—skin cancer	0.00336	0.00336	CcSEcCtD
Emtricitabine—Nausea—Vismodegib—skin cancer	0.00335	0.00335	CcSEcCtD
Emtricitabine—Pneumonia—Bleomycin—skin cancer	0.00333	0.00333	CcSEcCtD
Emtricitabine—Angioedema—Imiquimod—skin cancer	0.00333	0.00333	CcSEcCtD
Emtricitabine—Hypokalaemia—Temozolomide—skin cancer	0.0033	0.0033	CcSEcCtD
Emtricitabine—Breast disorder—Temozolomide—skin cancer	0.00328	0.00328	CcSEcCtD
Emtricitabine—Neutropenia—Dactinomycin—skin cancer	0.00324	0.00324	CcSEcCtD
Emtricitabine—Muscular weakness—Temozolomide—skin cancer	0.0032	0.0032	CcSEcCtD
Emtricitabine—Alanine aminotransferase increased—Temozolomide—skin cancer	0.0032	0.0032	CcSEcCtD
Emtricitabine—Cough—Imiquimod—skin cancer	0.00318	0.00318	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00318	0.00318	CcSEcCtD
Emtricitabine—Haematuria—Bleomycin—skin cancer	0.00316	0.00316	CcSEcCtD
Emtricitabine—Neuropathy—Docetaxel—skin cancer	0.00312	0.00312	CcSEcCtD
Emtricitabine—Pneumonia—Dactinomycin—skin cancer	0.00311	0.00311	CcSEcCtD
Emtricitabine—Arthralgia—Imiquimod—skin cancer	0.0031	0.0031	CcSEcCtD
Emtricitabine—Myalgia—Imiquimod—skin cancer	0.0031	0.0031	CcSEcCtD
Emtricitabine—Anxiety—Imiquimod—skin cancer	0.00309	0.00309	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00308	0.00308	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00301	0.00301	CcSEcCtD
Emtricitabine—Fatigue—Vemurafenib—skin cancer	0.00301	0.00301	CcSEcCtD
Emtricitabine—Nasopharyngitis—Fluorouracil—skin cancer	0.00299	0.00299	CcSEcCtD
Emtricitabine—Infection—Imiquimod—skin cancer	0.00295	0.00295	CcSEcCtD
Emtricitabine—Muscular weakness—Fluorouracil—skin cancer	0.00295	0.00295	CcSEcCtD
Emtricitabine—Neutropenia—Temozolomide—skin cancer	0.00293	0.00293	CcSEcCtD
Emtricitabine—Nervous system disorder—Imiquimod—skin cancer	0.00292	0.00292	CcSEcCtD
Emtricitabine—Upper respiratory tract infection—Temozolomide—skin cancer	0.00291	0.00291	CcSEcCtD
Emtricitabine—Skin disorder—Imiquimod—skin cancer	0.00289	0.00289	CcSEcCtD
Emtricitabine—Weight decreased—Temozolomide—skin cancer	0.00284	0.00284	CcSEcCtD
Emtricitabine—Hyperglycaemia—Temozolomide—skin cancer	0.00283	0.00283	CcSEcCtD
Emtricitabine—Pneumonia—Temozolomide—skin cancer	0.00281	0.00281	CcSEcCtD
Emtricitabine—Infestation NOS—Temozolomide—skin cancer	0.00279	0.00279	CcSEcCtD
Emtricitabine—Infestation—Temozolomide—skin cancer	0.00279	0.00279	CcSEcCtD
Emtricitabine—Depression—Temozolomide—skin cancer	0.00279	0.00279	CcSEcCtD
Emtricitabine—Hepatitis—Dactinomycin—skin cancer	0.00277	0.00277	CcSEcCtD
Emtricitabine—Body temperature increased—Vemurafenib—skin cancer	0.00276	0.00276	CcSEcCtD
Emtricitabine—Pharyngitis—Dactinomycin—skin cancer	0.00275	0.00275	CcSEcCtD
Emtricitabine—Neuropathy peripheral—Temozolomide—skin cancer	0.00274	0.00274	CcSEcCtD
Emtricitabine—Urinary tract infection—Temozolomide—skin cancer	0.00272	0.00272	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00271	0.00271	CcSEcCtD
Emtricitabine—Insomnia—Imiquimod—skin cancer	0.00269	0.00269	CcSEcCtD
Emtricitabine—Upper respiratory tract infection—Fluorouracil—skin cancer	0.00268	0.00268	CcSEcCtD
Emtricitabine—Paraesthesia—Imiquimod—skin cancer	0.00267	0.00267	CcSEcCtD
Emtricitabine—Dyspnoea—Imiquimod—skin cancer	0.00265	0.00265	CcSEcCtD
Emtricitabine—Hepatobiliary disease—Temozolomide—skin cancer	0.00264	0.00264	CcSEcCtD
Emtricitabine—Sinusitis—Temozolomide—skin cancer	0.00262	0.00262	CcSEcCtD
Emtricitabine—Dyspepsia—Imiquimod—skin cancer	0.00262	0.00262	CcSEcCtD
Emtricitabine—Pneumonia—Fluorouracil—skin cancer	0.00259	0.00259	CcSEcCtD
Emtricitabine—Infestation NOS—Fluorouracil—skin cancer	0.00257	0.00257	CcSEcCtD
Emtricitabine—Infestation—Fluorouracil—skin cancer	0.00257	0.00257	CcSEcCtD
Emtricitabine—Hypersensitivity—Vemurafenib—skin cancer	0.00257	0.00257	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Imiquimod—skin cancer	0.00257	0.00257	CcSEcCtD
Emtricitabine—Fatigue—Imiquimod—skin cancer	0.00256	0.00256	CcSEcCtD
Emtricitabine—Pain—Imiquimod—skin cancer	0.00254	0.00254	CcSEcCtD
Emtricitabine—Renal impairment—Docetaxel—skin cancer	0.00253	0.00253	CcSEcCtD
Emtricitabine—Neuropathy peripheral—Fluorouracil—skin cancer	0.00252	0.00252	CcSEcCtD
Emtricitabine—Dermatitis bullous—Docetaxel—skin cancer	0.00252	0.00252	CcSEcCtD
Emtricitabine—Hepatitis—Temozolomide—skin cancer	0.00251	0.00251	CcSEcCtD
Emtricitabine—Urinary tract infection—Fluorouracil—skin cancer	0.0025	0.0025	CcSEcCtD
Emtricitabine—Asthenia—Vemurafenib—skin cancer	0.0025	0.0025	CcSEcCtD
Emtricitabine—Pharyngitis—Temozolomide—skin cancer	0.00249	0.00249	CcSEcCtD
Emtricitabine—Urinary tract disorder—Temozolomide—skin cancer	0.00248	0.00248	CcSEcCtD
Emtricitabine—Pruritus—Vemurafenib—skin cancer	0.00247	0.00247	CcSEcCtD
Emtricitabine—Connective tissue disorder—Temozolomide—skin cancer	0.00247	0.00247	CcSEcCtD
Emtricitabine—Urethral disorder—Temozolomide—skin cancer	0.00246	0.00246	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Imiquimod—skin cancer	0.00243	0.00243	CcSEcCtD
Emtricitabine—Sinusitis—Fluorouracil—skin cancer	0.00242	0.00242	CcSEcCtD
Emtricitabine—Anaemia—Bleomycin—skin cancer	0.00239	0.00239	CcSEcCtD
Emtricitabine—Diarrhoea—Vemurafenib—skin cancer	0.00239	0.00239	CcSEcCtD
Emtricitabine—Urticaria—Imiquimod—skin cancer	0.00236	0.00236	CcSEcCtD
Emtricitabine—Abdominal pain—Imiquimod—skin cancer	0.00235	0.00235	CcSEcCtD
Emtricitabine—Body temperature increased—Imiquimod—skin cancer	0.00235	0.00235	CcSEcCtD
Emtricitabine—Rhinitis—Fluorouracil—skin cancer	0.00232	0.00232	CcSEcCtD
Emtricitabine—Dizziness—Vemurafenib—skin cancer	0.00231	0.00231	CcSEcCtD
Emtricitabine—Pharyngitis—Fluorouracil—skin cancer	0.00229	0.00229	CcSEcCtD
Emtricitabine—Immune system disorder—Temozolomide—skin cancer	0.00227	0.00227	CcSEcCtD
Emtricitabine—Mediastinal disorder—Temozolomide—skin cancer	0.00226	0.00226	CcSEcCtD
Emtricitabine—Cough—Bleomycin—skin cancer	0.00226	0.00226	CcSEcCtD
Emtricitabine—Anaemia—Dactinomycin—skin cancer	0.00223	0.00223	CcSEcCtD
Emtricitabine—Vomiting—Vemurafenib—skin cancer	0.00222	0.00222	CcSEcCtD
Emtricitabine—Myalgia—Bleomycin—skin cancer	0.0022	0.0022	CcSEcCtD
Emtricitabine—Rash—Vemurafenib—skin cancer	0.0022	0.0022	CcSEcCtD
Emtricitabine—Mental disorder—Temozolomide—skin cancer	0.0022	0.0022	CcSEcCtD
Emtricitabine—Dermatitis—Vemurafenib—skin cancer	0.0022	0.0022	CcSEcCtD
Emtricitabine—Hypersensitivity—Imiquimod—skin cancer	0.00219	0.00219	CcSEcCtD
Emtricitabine—Headache—Vemurafenib—skin cancer	0.00218	0.00218	CcSEcCtD
Emtricitabine—Malnutrition—Temozolomide—skin cancer	0.00218	0.00218	CcSEcCtD
Emtricitabine—Breast disorder—Docetaxel—skin cancer	0.00218	0.00218	CcSEcCtD
Emtricitabine—Nasopharyngitis—Docetaxel—skin cancer	0.00216	0.00216	CcSEcCtD
Emtricitabine—Asthenia—Imiquimod—skin cancer	0.00213	0.00213	CcSEcCtD
Emtricitabine—Alanine aminotransferase increased—Docetaxel—skin cancer	0.00213	0.00213	CcSEcCtD
Emtricitabine—Back pain—Temozolomide—skin cancer	0.00211	0.00211	CcSEcCtD
Emtricitabine—Pruritus—Imiquimod—skin cancer	0.0021	0.0021	CcSEcCtD
Emtricitabine—Infection—Bleomycin—skin cancer	0.0021	0.0021	CcSEcCtD
Emtricitabine—Nausea—Vemurafenib—skin cancer	0.00207	0.00207	CcSEcCtD
Emtricitabine—Thrombocytopenia—Bleomycin—skin cancer	0.00207	0.00207	CcSEcCtD
Emtricitabine—Myalgia—Dactinomycin—skin cancer	0.00206	0.00206	CcSEcCtD
Emtricitabine—Diarrhoea—Imiquimod—skin cancer	0.00203	0.00203	CcSEcCtD
Emtricitabine—Anaemia—Temozolomide—skin cancer	0.00202	0.00202	CcSEcCtD
Emtricitabine—Angioedema—Temozolomide—skin cancer	0.002	0.002	CcSEcCtD
Emtricitabine—Dizziness—Imiquimod—skin cancer	0.00197	0.00197	CcSEcCtD
Emtricitabine—Infection—Dactinomycin—skin cancer	0.00196	0.00196	CcSEcCtD
Emtricitabine—Neutropenia—Docetaxel—skin cancer	0.00195	0.00195	CcSEcCtD
Emtricitabine—Thrombocytopenia—Dactinomycin—skin cancer	0.00193	0.00193	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00192	0.00192	CcSEcCtD
Emtricitabine—Cough—Temozolomide—skin cancer	0.00191	0.00191	CcSEcCtD
Emtricitabine—Paraesthesia—Bleomycin—skin cancer	0.0019	0.0019	CcSEcCtD
Emtricitabine—Vomiting—Imiquimod—skin cancer	0.00189	0.00189	CcSEcCtD
Emtricitabine—Weight decreased—Docetaxel—skin cancer	0.00189	0.00189	CcSEcCtD
Emtricitabine—Dyspnoea—Bleomycin—skin cancer	0.00188	0.00188	CcSEcCtD
Emtricitabine—Rash—Imiquimod—skin cancer	0.00188	0.00188	CcSEcCtD
Emtricitabine—Dermatitis—Imiquimod—skin cancer	0.00187	0.00187	CcSEcCtD
Emtricitabine—Pneumonia—Docetaxel—skin cancer	0.00187	0.00187	CcSEcCtD
Emtricitabine—Headache—Imiquimod—skin cancer	0.00186	0.00186	CcSEcCtD
Emtricitabine—Anaemia—Fluorouracil—skin cancer	0.00186	0.00186	CcSEcCtD
Emtricitabine—Myalgia—Temozolomide—skin cancer	0.00186	0.00186	CcSEcCtD
Emtricitabine—Arthralgia—Temozolomide—skin cancer	0.00186	0.00186	CcSEcCtD
Emtricitabine—Infestation NOS—Docetaxel—skin cancer	0.00186	0.00186	CcSEcCtD
Emtricitabine—Infestation—Docetaxel—skin cancer	0.00186	0.00186	CcSEcCtD
Emtricitabine—Anxiety—Temozolomide—skin cancer	0.00185	0.00185	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00185	0.00185	CcSEcCtD
Emtricitabine—Renal failure—Docetaxel—skin cancer	0.00183	0.00183	CcSEcCtD
Emtricitabine—Neuropathy peripheral—Docetaxel—skin cancer	0.00182	0.00182	CcSEcCtD
Emtricitabine—Pain—Bleomycin—skin cancer	0.00181	0.00181	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.0018	0.0018	CcSEcCtD
Emtricitabine—Infection—Temozolomide—skin cancer	0.00177	0.00177	CcSEcCtD
Emtricitabine—Nausea—Imiquimod—skin cancer	0.00177	0.00177	CcSEcCtD
Emtricitabine—Hepatobiliary disease—Docetaxel—skin cancer	0.00176	0.00176	CcSEcCtD
Emtricitabine—Nervous system disorder—Temozolomide—skin cancer	0.00175	0.00175	CcSEcCtD
Emtricitabine—Thrombocytopenia—Temozolomide—skin cancer	0.00174	0.00174	CcSEcCtD
Emtricitabine—Skin disorder—Temozolomide—skin cancer	0.00173	0.00173	CcSEcCtD
Emtricitabine—Myalgia—Fluorouracil—skin cancer	0.00171	0.00171	CcSEcCtD
Emtricitabine—Fatigue—Dactinomycin—skin cancer	0.0017	0.0017	CcSEcCtD
Emtricitabine—Pain—Dactinomycin—skin cancer	0.00169	0.00169	CcSEcCtD
Emtricitabine—Urticaria—Bleomycin—skin cancer	0.00168	0.00168	CcSEcCtD
Emtricitabine—Rhinitis—Docetaxel—skin cancer	0.00167	0.00167	CcSEcCtD
Emtricitabine—Body temperature increased—Bleomycin—skin cancer	0.00167	0.00167	CcSEcCtD
Emtricitabine—Hepatitis—Docetaxel—skin cancer	0.00167	0.00167	CcSEcCtD
Emtricitabine—Pharyngitis—Docetaxel—skin cancer	0.00166	0.00166	CcSEcCtD
Emtricitabine—Urinary tract disorder—Docetaxel—skin cancer	0.00165	0.00165	CcSEcCtD
Emtricitabine—Connective tissue disorder—Docetaxel—skin cancer	0.00164	0.00164	CcSEcCtD
Emtricitabine—Urethral disorder—Docetaxel—skin cancer	0.00164	0.00164	CcSEcCtD
Emtricitabine—Infection—Fluorouracil—skin cancer	0.00163	0.00163	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00162	0.00162	CcSEcCtD
Emtricitabine—Insomnia—Temozolomide—skin cancer	0.00161	0.00161	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Dactinomycin—skin cancer	0.00161	0.00161	CcSEcCtD
Emtricitabine—Nervous system disorder—Fluorouracil—skin cancer	0.00161	0.00161	CcSEcCtD
Emtricitabine—Thrombocytopenia—Fluorouracil—skin cancer	0.00161	0.00161	CcSEcCtD
Emtricitabine—Paraesthesia—Temozolomide—skin cancer	0.0016	0.0016	CcSEcCtD
Emtricitabine—Dyspnoea—Temozolomide—skin cancer	0.00159	0.00159	CcSEcCtD
Emtricitabine—Dyspepsia—Temozolomide—skin cancer	0.00157	0.00157	CcSEcCtD
Emtricitabine—Abdominal pain—Dactinomycin—skin cancer	0.00156	0.00156	CcSEcCtD
Emtricitabine—Body temperature increased—Dactinomycin—skin cancer	0.00156	0.00156	CcSEcCtD
Emtricitabine—Hypersensitivity—Bleomycin—skin cancer	0.00156	0.00156	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Temozolomide—skin cancer	0.00154	0.00154	CcSEcCtD
Emtricitabine—Fatigue—Temozolomide—skin cancer	0.00154	0.00154	CcSEcCtD
Emtricitabine—Pain—Temozolomide—skin cancer	0.00152	0.00152	CcSEcCtD
Emtricitabine—Asthenia—Bleomycin—skin cancer	0.00152	0.00152	CcSEcCtD
Emtricitabine—Immune system disorder—Docetaxel—skin cancer	0.00151	0.00151	CcSEcCtD
Emtricitabine—Mediastinal disorder—Docetaxel—skin cancer	0.0015	0.0015	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.0015	0.0015	CcSEcCtD
Emtricitabine—Pruritus—Bleomycin—skin cancer	0.00149	0.00149	CcSEcCtD
Emtricitabine—Insomnia—Fluorouracil—skin cancer	0.00149	0.00149	CcSEcCtD
Emtricitabine—Paraesthesia—Fluorouracil—skin cancer	0.00147	0.00147	CcSEcCtD
Emtricitabine—Dyspnoea—Fluorouracil—skin cancer	0.00146	0.00146	CcSEcCtD
Emtricitabine—Mental disorder—Docetaxel—skin cancer	0.00146	0.00146	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Temozolomide—skin cancer	0.00146	0.00146	CcSEcCtD
Emtricitabine—Malnutrition—Docetaxel—skin cancer	0.00145	0.00145	CcSEcCtD
Emtricitabine—Hypersensitivity—Dactinomycin—skin cancer	0.00145	0.00145	CcSEcCtD
Emtricitabine—Dyspepsia—Fluorouracil—skin cancer	0.00145	0.00145	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00142	0.00142	CcSEcCtD
Emtricitabine—Urticaria—Temozolomide—skin cancer	0.00142	0.00142	CcSEcCtD
Emtricitabine—Asthenia—Dactinomycin—skin cancer	0.00141	0.00141	CcSEcCtD
Emtricitabine—Abdominal pain—Temozolomide—skin cancer	0.00141	0.00141	CcSEcCtD
Emtricitabine—Body temperature increased—Temozolomide—skin cancer	0.00141	0.00141	CcSEcCtD
Emtricitabine—Back pain—Docetaxel—skin cancer	0.0014	0.0014	CcSEcCtD
Emtricitabine—Pain—Fluorouracil—skin cancer	0.0014	0.0014	CcSEcCtD
Emtricitabine—Diarrhoea—Dactinomycin—skin cancer	0.00135	0.00135	CcSEcCtD
Emtricitabine—Vomiting—Bleomycin—skin cancer	0.00134	0.00134	CcSEcCtD
Emtricitabine—Anaemia—Docetaxel—skin cancer	0.00134	0.00134	CcSEcCtD
Emtricitabine—Rash—Bleomycin—skin cancer	0.00133	0.00133	CcSEcCtD
Emtricitabine—Dermatitis—Bleomycin—skin cancer	0.00133	0.00133	CcSEcCtD
Emtricitabine—Hypersensitivity—Temozolomide—skin cancer	0.00131	0.00131	CcSEcCtD
Emtricitabine—Urticaria—Fluorouracil—skin cancer	0.0013	0.0013	CcSEcCtD
Emtricitabine—Body temperature increased—Fluorouracil—skin cancer	0.0013	0.0013	CcSEcCtD
Emtricitabine—Asthenia—Temozolomide—skin cancer	0.00128	0.00128	CcSEcCtD
Emtricitabine—Cough—Docetaxel—skin cancer	0.00127	0.00127	CcSEcCtD
Emtricitabine—Pruritus—Temozolomide—skin cancer	0.00126	0.00126	CcSEcCtD
Emtricitabine—Nausea—Bleomycin—skin cancer	0.00125	0.00125	CcSEcCtD
Emtricitabine—Vomiting—Dactinomycin—skin cancer	0.00125	0.00125	CcSEcCtD
Emtricitabine—Rash—Dactinomycin—skin cancer	0.00124	0.00124	CcSEcCtD
Emtricitabine—Arthralgia—Docetaxel—skin cancer	0.00124	0.00124	CcSEcCtD
Emtricitabine—Myalgia—Docetaxel—skin cancer	0.00124	0.00124	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00123	0.00123	CcSEcCtD
Emtricitabine—Diarrhoea—Temozolomide—skin cancer	0.00122	0.00122	CcSEcCtD
Emtricitabine—Hypersensitivity—Fluorouracil—skin cancer	0.00121	0.00121	CcSEcCtD
Emtricitabine—Dizziness—Temozolomide—skin cancer	0.00118	0.00118	CcSEcCtD
Emtricitabine—Infection—Docetaxel—skin cancer	0.00118	0.00118	CcSEcCtD
Emtricitabine—Nausea—Dactinomycin—skin cancer	0.00117	0.00117	CcSEcCtD
Emtricitabine—Nervous system disorder—Docetaxel—skin cancer	0.00116	0.00116	CcSEcCtD
Emtricitabine—Pruritus—Fluorouracil—skin cancer	0.00116	0.00116	CcSEcCtD
Emtricitabine—Thrombocytopenia—Docetaxel—skin cancer	0.00116	0.00116	CcSEcCtD
Emtricitabine—Skin disorder—Docetaxel—skin cancer	0.00115	0.00115	CcSEcCtD
Emtricitabine—Vomiting—Temozolomide—skin cancer	0.00113	0.00113	CcSEcCtD
Emtricitabine—Rash—Temozolomide—skin cancer	0.00112	0.00112	CcSEcCtD
Emtricitabine—Diarrhoea—Fluorouracil—skin cancer	0.00112	0.00112	CcSEcCtD
Emtricitabine—Dermatitis—Temozolomide—skin cancer	0.00112	0.00112	CcSEcCtD
Emtricitabine—Headache—Temozolomide—skin cancer	0.00112	0.00112	CcSEcCtD
Emtricitabine—Dizziness—Fluorouracil—skin cancer	0.00109	0.00109	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00108	0.00108	CcSEcCtD
Emtricitabine—Insomnia—Docetaxel—skin cancer	0.00107	0.00107	CcSEcCtD
Emtricitabine—Paraesthesia—Docetaxel—skin cancer	0.00106	0.00106	CcSEcCtD
Emtricitabine—Nausea—Temozolomide—skin cancer	0.00106	0.00106	CcSEcCtD
Emtricitabine—Dyspnoea—Docetaxel—skin cancer	0.00106	0.00106	CcSEcCtD
Emtricitabine—Vomiting—Fluorouracil—skin cancer	0.00104	0.00104	CcSEcCtD
Emtricitabine—Dyspepsia—Docetaxel—skin cancer	0.00104	0.00104	CcSEcCtD
Emtricitabine—Rash—Fluorouracil—skin cancer	0.00104	0.00104	CcSEcCtD
Emtricitabine—Dermatitis—Fluorouracil—skin cancer	0.00103	0.00103	CcSEcCtD
Emtricitabine—Headache—Fluorouracil—skin cancer	0.00103	0.00103	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Docetaxel—skin cancer	0.00102	0.00102	CcSEcCtD
Emtricitabine—Fatigue—Docetaxel—skin cancer	0.00102	0.00102	CcSEcCtD
Emtricitabine—Pain—Docetaxel—skin cancer	0.00101	0.00101	CcSEcCtD
Emtricitabine—Nausea—Fluorouracil—skin cancer	0.000975	0.000975	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Docetaxel—skin cancer	0.000969	0.000969	CcSEcCtD
Emtricitabine—Body temperature increased—Docetaxel—skin cancer	0.000937	0.000937	CcSEcCtD
Emtricitabine—Abdominal pain—Docetaxel—skin cancer	0.000937	0.000937	CcSEcCtD
Emtricitabine—Hypersensitivity—Docetaxel—skin cancer	0.000873	0.000873	CcSEcCtD
Emtricitabine—Asthenia—Docetaxel—skin cancer	0.00085	0.00085	CcSEcCtD
Emtricitabine—Pruritus—Docetaxel—skin cancer	0.000839	0.000839	CcSEcCtD
Emtricitabine—Diarrhoea—Docetaxel—skin cancer	0.000811	0.000811	CcSEcCtD
Emtricitabine—Dizziness—Docetaxel—skin cancer	0.000784	0.000784	CcSEcCtD
Emtricitabine—Vomiting—Docetaxel—skin cancer	0.000754	0.000754	CcSEcCtD
Emtricitabine—Rash—Docetaxel—skin cancer	0.000747	0.000747	CcSEcCtD
Emtricitabine—Dermatitis—Docetaxel—skin cancer	0.000747	0.000747	CcSEcCtD
Emtricitabine—Headache—Docetaxel—skin cancer	0.000742	0.000742	CcSEcCtD
Emtricitabine—Nausea—Docetaxel—skin cancer	0.000704	0.000704	CcSEcCtD
